ArticleThe American journal of gastroenterology2025

Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.

Cynthia Levy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.